| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99215 |
Prolong outpt/office vis |
22,678 |
21,164 |
$3.84M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,546 |
11,625 |
$1.99M |
| S9083 |
Global fee urgent care centers |
9,293 |
8,545 |
$1.17M |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
35,380 |
26,562 |
$1.08M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
29,779 |
28,303 |
$582K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,591 |
2,341 |
$450K |
| 99205 |
Prolong outpt/office vis |
1,799 |
1,702 |
$250K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
17,790 |
17,097 |
$188K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,220 |
1,145 |
$176K |
| 71046 |
Radiologic examination, chest; 2 views |
2,579 |
2,455 |
$131K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,595 |
1,531 |
$117K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,760 |
1,625 |
$115K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
500 |
470 |
$89K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,246 |
2,136 |
$89K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,456 |
1,330 |
$87K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
324 |
317 |
$53K |
| 73610 |
|
292 |
280 |
$32K |
| 74019 |
|
458 |
447 |
$23K |
| 81001 |
|
2,419 |
2,302 |
$23K |
| 73630 |
|
253 |
246 |
$20K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
480 |
442 |
$11K |
| 94664 |
|
1,119 |
1,023 |
$9K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
432 |
411 |
$8K |
| 84703 |
|
181 |
174 |
$5K |
| 73140 |
|
104 |
101 |
$5K |
| 85027 |
|
116 |
113 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
428 |
420 |
$3K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
15 |
12 |
$3K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
22 |
15 |
$3K |
| 87807 |
|
547 |
508 |
$2K |
| 87077 |
|
382 |
360 |
$2K |
| 80047 |
|
12 |
12 |
$2K |
| 73110 |
|
15 |
15 |
$2K |
| 51701 |
|
38 |
36 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,777 |
1,677 |
$802.02 |
| 73564 |
|
12 |
12 |
$757.08 |
| 87581 |
|
461 |
450 |
$373.44 |
| 87045 |
|
18 |
18 |
$340.61 |
| 29515 |
|
76 |
75 |
$117.93 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,485 |
1,409 |
$90.45 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
89 |
85 |
$47.04 |
| 85007 |
|
103 |
100 |
$0.00 |
| 87186 |
|
245 |
229 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
49 |
48 |
$0.00 |
| 87427 |
|
18 |
18 |
$0.00 |
| 29125 |
|
15 |
15 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
129 |
122 |
$0.00 |
| 87486 |
|
407 |
400 |
$0.00 |